CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.  Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck’s Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer.  A second clinical trial combining Ampligen with Keytruda in ovarian cancer is scheduled to launch later this month at the University of Pittsburgh.